Cargando…

Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study

In randomized controlled trials (RCTs), sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors have been shown to confer glycaemic and extra‐glycaemic benefits. The DARWIN‐T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes) study was a multicentre retrospective study designed to evaluate the base...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fadini, Gian Paolo, Zatti, Giancarlo, Baldi, Ileana, Bottigliengo, Daniele, Consoli, Agostino, Giaccari, Andrea, Sesti, Giorgio, Avogaro, Angelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2018
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175069/ https://www.ncbi.nlm.nih.gov/pubmed/29516612 http://dx.doi.org/10.1111/dom.13280

Ejemplares similares

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Similar effectiveness of dapagliflozin and GLP‐1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Assessment of Glucose Lowering Medications’ Effectiveness for Cardiovascular Clinical Risk Management of Real-World Patients with Type 2 Diabetes: Targeted Maximum Likelihood Estimation under Model Misspecification and Missing Outcomes
por: Sciannameo, Veronica, et al.
Publicado: (2022)

Comparative effectiveness of exenatide once‐weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta‐analysis of observational studies
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
por: Fadini, Gian Paolo, et al.
Publicado: (2017)

Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study
por: Morieri, M. L., et al.
Publicado: (2023)

Efficacy of Dapagliflozin in Southern Europe Across the Spectrum of Characteristics of Type 2 Diabetes: An International Real-World Analysis
por: Fadini, Gian Paolo, et al.
Publicado: (2022)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
por: Avogaro, Angelo, et al.
Publicado: (2016)

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
por: Bonora, Benedetta Maria, et al.
Publicado: (2019)

Effectiveness of adding alarms to flash glucose monitoring in adults with type 1 diabetes under routine care
por: Boscari, Federico, et al.
Publicado: (2022)

It Is All in the Blood: The Multifaceted Contribution of Circulating Progenitor Cells in Diabetic Complications
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care
por: Morieri, Mario Luca, et al.
Publicado: (2022)

Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study
por: Longato, Enrico, et al.
Publicado: (2021)

Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Managing diabetes in diabetic patients with COVID: where do we start from?
por: Avogaro, Angelo, et al.
Publicado: (2021)

Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Response to Chia Siang Kow and colleagues
por: Avogaro, Angelo, et al.
Publicado: (2022)

Fixed versus flexible combination of GLP‐1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study
por: Morieri, Mario Luca, et al.
Publicado: (2019)

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
por: Bonora, Benedetta Maria, et al.
Publicado: (2021)

Challenges and opportunities in real‐world evidence on the renal effects of sodium‐glucose cotransporter‐2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2021)

The Endothelium Abridges Insulin Resistance to Premature Aging
por: Avogaro, Angelo, et al.
Publicado: (2013)

Amelioration of Glucose Control Mobilizes Circulating Pericyte Progenitor Cells in Type 2 Diabetic Patients with Microangiopathy
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

Endothelial Dysfunction in Diabetes: The role of reparatory mechanisms
por: Avogaro, Angelo, et al.
Publicado: (2011)

Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in Italy
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Time-resolved trajectory of glucose lowering medications and cardiovascular outcomes in type 2 diabetes: a recurrent neural network analysis
por: Longato, Enrico, et al.
Publicado: (2022)

Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies
por: Fadini, Gian Paolo, et al.
Publicado: (2021)

The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients
por: Poncina, Nicol, et al.
Publicado: (2014)

A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes
por: Fadini, Gian Paolo, et al.
Publicado: (2017)

Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
por: Longato, Enrico, et al.
Publicado: (2020)

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
por: Longato, Enrico, et al.
Publicado: (2020)

Phenomapping of Patients with Primary Breast Cancer Using Machine Learning-Based Unsupervised Cluster Analysis
por: Ferro, Sara, et al.
Publicado: (2021)

Mitochondrial Calcium Uptake Is Instrumental to Alternative Macrophage Polarization and Phagocytic Activity
por: Tedesco, Serena, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kgeni2fl6b521i17s0eutoab7i